Appendix 4C – quarterly
CLINUVEL PHARMACEUTICALS LTD today announced its Appendix 4C – Quarterly Cashflow Report...
Read MoreCLINUVEL Newsletter
Dear shareholders, friends, As a new world presents itself indicating that the...
Read MoreMedia Release - Second Afamelanotide Formulation
PRÉNUMBRA®- CLINUVEL’S SECOND AFAMELANOTIDE FORMULATION Drug to be evaluated in patients with...
Read MorePRÉNUMBRA® – New Liquid Afamelanotide Presentation
EXECUTIVE SUMMARY• PRÉNUMBRA® non-solid dosage form of afamelanotide• Active life-cycle management of...
Read More